The BioEscalator, the University of Oxford’s biomedical incubator, is very proud to be home to a pioneering collection of companies tackling profound medical challenges. These leading firms are profiled in the newly launched second edition of our Portfolio, a valuable annual guide to the BioEscalator tenant community for investors, partners and anyone interested in biomedical innovation.
Portfolio 2026 includes an introduction from Charlotte Casebourne Stock, Executive Partner at company creator and builder Yarvie and co-founder of Oxford spin-out Theolytics. With profiles of 14 companies creating the future of healthcare, it brings an exciting insight into the R&D taking place at the BioEscalator. There’s also an update on our alumni – companies which have graduated from the BioEscalator – and our achievement metrics.
We hope you find this Portfolio 2026 an enjoyable guide to our tenants’ activities.
The document can be accessed here https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=bioescalator-portfolio
